Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response

Roque, Valentin; Jessop, Maryam; Pereira, Luisa Roldao; Gape, Paul; Dizdarevic, Sabina; Sousa, Eva; Carolino, Elizabete

doi:10.1097/mnm.0000000000001005

Cited by 7 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 4 , 10 – 13 The bone scan index has also been used as a metastatic bone disease quantifier and predictor of Ra-223 biochemical responses; however, we did not collect data on the bone scan index in the present study. 14 – 16 PSA levels were previously shown to sometimes become elevated during the first three cycles of Ra-223 due to the flare phenomenon; however, the flare phenomenon was not detected in the present study. 17 The present results showed that Hb, leukocyte, and ALP levels were significantly reduced in patients after the planned six Ra-223 injections; however, it was considered to be difficult to evaluate them individually.…”

Section: Discussioncontrasting

confidence: 85%

“…PSADT is a commonly used indicator of distant metastasis among patients treated with ADT and radiation therapy; however, it currently remains unclear whether PSADT after treatment with Ra-223 reflects therapeutic effects and the subsequent clinical course. 4 , 11 – 16 Based on the present study, PSADT after the Ra-223 treatment was a useful indicator for estimating the clinical course following treatment.…”

Section: Discussionmentioning

confidence: 76%

See 1 more Smart Citation

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

et al. 2023

View full text Add to dashboard Cite

Objectives: To identify useful biomarkers by reviewing laboratory data for a predictor of the clinical course following treatment with radium-223 dichloride (Ra-223) in patients with metastatic castration-resistant prostate cancer. Methods: Eighteen metastatic castration-resistant prostate cancer patients who were administered Ra-223 at our hospital were retrospectively enrolled in this study. Prostate-specific antigen doubling times before and after the administration of Ra-223 were evaluated as prognostic factors for metastatic castration-resistant prostate cancer patients treated with Ra-223 using the Kaplan–Meier method and Log-rank test. Results: Four patients failed to complete the planned six-time Ra-223 treatments with the exacerbation of their condition. In the 14 patients who completed the planned Ra-223 treatment, before the Ra-223 treatment, no significant differences were observed in overall survival between patients with prostate-specific antigen doubling time of 6 months or less and those with prostate-specific antigen doubling time of more than 6 months or stable ( p = 0.642). Following the completion of the Ra-223 treatment, overall survival was significantly shorter in patients with prostate-specific antigen doubling time of 6 months or less than in those with prostate-specific antigen doubling time of more than 6 months or stable ( p = 0.007). Conclusion: Prostate-specific antigen doubling time after the Ra-223 treatment is a useful predictor of the clinical course following treatment in metastatic castration-resistant prostate cancer patients.

show abstract

Section: Discussioncontrasting

confidence: 85%

Section: Discussionmentioning

confidence: 76%

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

et al. 2023

View full text Add to dashboard Cite

show abstract

“…On the other hand, many studies already showed the prognostic value of circulating PSA and ALP at baseline, as biochemical indicators of the tumor extent [28,[31][32][33][34][35][36][37][38]. This is coherent with the unfavorable prognosis observed in patients with massive bone metastases (> 20) at the bone scan or high tumor burden assessed with more sophisticated quantification approaches [32,[39][40][41][42][43].…”

Section: Discussionmentioning

confidence: 83%

The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)

Bauckneht

Rebuzzi

Signori

et al. 2021

Eur J Nucl Med Mol Imaging

View full text Add to dashboard Cite

Purpose To combine peripheral blood indices and clinical factors in a prognostic score for metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 dichloride ([223Ra]RaCl2). Patients and methods Baseline neutrophil-to-lymphocyte ratio (NLR), derived NLR (donor), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), systemic inflammation index (SII), Eastern Cooperative Oncology Group performance status (ECOG PS), Gleason score (GS) group, number of bone metastases, prostate-specific antigen (PSA), alkaline phosphatase (ALP), line of therapy, previous chemotherapy, and the presence of lymphadenopathies were collected from seven Italian centers between 2013 and 2020. Lab and clinical data were assessed in correlation with the overall survival (OS). Inflammatory indices were then included separately in the multivariable analyses with the prognostic clinical factors. The model with the highest discriminative ability (c-index) was chosen to develop the BIO-Ra score. Results Five hundred and nineteen mCRPC patients (median OS: 19.9 months) were enrolled. Higher NLR, dNLR, PLR, and SII and lower LMR predicted worse OS (all with a p < 0.001). The multivariable model including NLR, ECOG PS, number of bone metastases, ALP, and PSA (c-index: 0.724) was chosen to develop the BIO-Ra score. Using the Schneeweiss scoring system, the BIO-Ra score identified three prognostic groups (36%, 27.3%, and 36.6% patients, respectively) with distinct median OS (31, 26.6, and 9.6 months, respectively; hazard ratio: 1.62, p = 0.008 for group 2 vs. 1 and 5.77, p < 0.001 for group 3 vs. 1). Conclusions The BIO-Ra score represents an easy and widely applicable tool for the prognostic stratification of mCRPC patients treated with [223Ra]RaCl2 with no additional costs.

show abstract

“…SPECT/CT imaging has gradually become widely accepted in the evaluation of DTC due to its ability to accurately locate and characterize abnormal lesions with accumulated radioactive nuclides, which affects staging, risk stratification, and clinical therapy ( 17 ). With the advancement of imaging technology, quantitative parameters of SPECT/CT have become vital imaging markers for disease diagnosis ( 18 ), therapy response evaluation ( 19 , 20 ), therapy guidance ( 9 , 21 ), and disease monitoring ( 22 , 23 ). However, research on the quantitative parameters of SPECT/CT imaging 3 days after RAI adjuvant therapy has been relatively limited.…”

Section: Discussionmentioning

confidence: 99%

Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer

Mao,

Lin,

Wang

et al. 2024

Quant Imaging Med Surg

View full text Add to dashboard Cite

Background Single-photon emission computed tomography-computed tomography (SPECT/CT) quantification has emerged as a valuable tool for assessing disease prognosis by accurately identifying and characterizing abnormal lesions with accumulated radionuclides. Papillary thyroid carcinoma (PTC) is the most prevalent type of thyroid cancer, and radioactive iodine (RAI) therapy is a standard treatment following total thyroidectomy. This study aimed to explore the potential utility the quantitative parameters of the thyroid bed under iodine-131 (I-131) SPECT/CT in the efficacy of RAI adjuvant therapy for patients with PTC. Methods The retrospective cohort study enrolled 107 patients with PTC who underwent RAI adjuvant therapy from June 2020 to January 2023. Three days after the RAI adjuvant therapy, all patients underwent I-131 whole-body scans and SPECT/CT imaging. The quantitative parameters, including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), and percent injected dose (%ID), were measured using image analysis software based on I-131 SPECT/CT thyroid bed uptake. Successful therapy was defined as inhibitory thyroglobulin (Tg) <0.2 ng/mL with negative thyroglobulin antibody (TgAb) and negative imaging examination 6 months after RAI adjuvant therapy. The relationship between the quantitative parameters and the treatment efficacy, in addition to the potential influencing factors, were analyzed. Results The quantitative parameters from the successful group [SUVmax: median 6.15 g/mL, interquartile range (IQR) 2.34–13.80 g/mL; SUVmean: median 2.02 g/mL, IQR 0.89–4.93 g/mL; %ID: median 2.00%, IQR 1.00–4.00%] were significantly lower than those from the unsuccessful group (SUVmax: median 19.03 g/mL, IQR 5.31–45.10 g/mL, SUVmean 4.64 g/mL, IQR 2.07–19.05 g/mL; %ID: median 8.00%, IQR 3.00–18.00%) (SUVmax: Z=−3.755; SUVmean; Z=−3.671; %ID: Z=−4.070; all P values <0.001). SUVmax, SUVmean and %ID were positively correlated with the stimulated thyroglobulin (sTg) and inhibitory Tg at 6 months after RAI adjuvant therapy, respectively (all P values <0.001). SUVmax [odds ratio (OR) =1.045], SUVmean (OR =1.130), and %ID (OR =1.092) were predictive factors for the failure of RAI adjuvant therapy (all P values <0.001). Conclusions Our study suggested that quantitative parameters (SUVmax, SUVmean, and %ID) derived from I-131 SPECT/CT imaging of the thyroid bed can serve as useful tools for predicting therapy outcomes following RAI adjuvant therapy.

show abstract

Bone scan index as metastatic bone disease quantifier and predictor of radium-223-dichloride biochemical response

Cited by 7 publications

References 23 publications

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

Prostate-specific antigen doubling time following radium-223 treatment as a predictor of the clinical course in patients with metastatic castration-resistant prostate cancer

The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)

Correlation analysis between the quantitative parameters of iodine-131 single-photon emission computed tomography-computed tomography thyroid bed uptake and the efficacy of radioactive iodine adjuvant therapy for papillary thyroid cancer

Contact Info

Product

Resources

About